Valbiotis: Strong Market Entry with Strategic Expansion and New Launches

Valbiotis, a French laboratory, has reported a successful start to 2025, aligning with its strategic goals. Key achievements include signing agreements with five pharmacy networks and preparing for the launch of a new product, TOTUM•854, expected by June. This aligns with their multi-channel marketing strategy, expanding their presence in over 1,500 pharmacies across France.

The company's commercial indicators are promising, showing significant growth in Q1 2025. Pharmacy restocking rates have increased, and online orders, as well as in-store transactions, have tripled since Q4 2024. Sales have nearly doubled, indicating a positive trajectory for 2025.

Valbiotis remains committed to its 2027 and 2030 financial targets, aiming for at least €25 million in annual sales in France by 2027 and €100 million globally by 2030. This growth will rely on continued innovation and international partnerships.